4/A//SEC Filing
Dudley Robert Michael 4/A
Accession 0001104659-23-071204
CIK 0001829635other
Filed
Jun 13, 8:00 PM ET
Accepted
Jun 14, 4:16 PM ET
Size
5.6 KB
Accession
0001104659-23-071204
Insider Transaction Report
Form 4/AAmended
Dudley Robert Michael
DirectorChief Executive Officer10% Owner
Transactions
- Purchase
Common Stock
2023-06-09$2.76/sh+19,000$52,440→ 61,155 total
Footnotes (2)
- [F1]Reflects the weighted average purchase price for shares of common stock purchased. Actual purchase prices for the shares purchased ranged from $2.675 to $2.85. The Reporting Person undertakes to provide TransCode Therapeutics, Inc. (the "Company"), any security holder of the Company or the staff of the Securities and Exchange Commission full information regarding the number of shares purchased at each separate price.
- [F2]This Form 4/A amends the Form 4 originally filed on June 13, 2023 solely to correct the amount reported in Table I, Column 5. Due to an administrative error, the amount reported on the original Form 4 was not adjusted to reflect a 1-for-20 reverse stock split of the Company's common stock, which became effective as of May 22, 2023.
Documents
Issuer
Transcode Therapeutics, Inc.
CIK 0001829635
Entity typeother
Related Parties
1- filerCIK 0001854161
Filing Metadata
- Form type
- 4/A
- Filed
- Jun 13, 8:00 PM ET
- Accepted
- Jun 14, 4:16 PM ET
- Size
- 5.6 KB